This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-12 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Nonclassical === Nonclassical describes those carbonyl complexes where νCO is higher than that for free carbon monoxide. In nonclassical CO complexes, the C-O distance is shorter than free CO (113.7 pm). The structure of [Fe(CO)6]2+, with dC-O = 112.9 pm, illustrates this effect. These complexes are usually cationic, sometimes dicationic.
The sub-title of the book is, as far as we are aware, a neologism, coined by one of us (A.L.B.), and the word is defined by the main title of the book, which could have been even more explicitly, if more verbosely, expressed as "The Identification and the Comparative Evaluation, Qualitative and Quantitative, of Drug Activities". The term has an etymological precedent in the now widely accepted "Econometrics". We hope it will prove useful for distinguishing the kind of measurement discussed and described in this book from what is nowadays called bioassay; although the same techniques sometimes serve for both, their objectives are not at all identical.
Action Game – Half-Life 2 Animation – Half-Life 2 Art Direction – Half-Life 2 Audio Achievement – Call of Duty: Finest Hour Best Game – Half-Life 2 Children's – Donkey Konga GameCube – Prince of Persia: Warrior Within Handheld – Colin McRae Rally 2005 Mobile Game – BlueTooth BiPlanes Online Multiplayer – Half-Life 2 Original Music – Hitman: Contracts Originality – SingStar/Singstar Party PC – Half-Life 2 PS2 – Burnout 3: Takedown Racing – Burnout 3: Takedown Sports – Pro Evolution Soccer 4 Sunday Times Reader Award for Games – Football Manager 2005 Technical Direction – Burnout 3: Takedown Xbox – Halo 2 Special Award (Games) – Sam Houser & Leslie Benzies
Shakey's Pizza is a pizza restaurant chain based in the United States and the Philippines. Founded in 1954, it was the first franchise pizza chain in the United States. In 1968, the chain had 342 locations. As of April 2026, the chain had about 500 stores globally and 43 in the United States. Currently, the stores can be found in the states of California and Washington, as well as in the Philippines, Singapore and Japan.
Sources: en.wikipedia.org
Currently approved GnRH antagonists include the peptide molecules abarelix, cetrorelix, degarelix, and ganirelix and the small-molecule compounds elagolix and relugolix. GnRH antagonists are administered by subcutaneous injection (cetrorelix, degarelix, ganirelix), by intramuscular injection (abarelix), or by oral administration (elagolix, relugolix). Another non-peptide and orally-active GnRH antagonist that is in development is linzagolix.
The protein kinase domain is a structurally conserved protein domain containing the catalytic function of protein kinases. Protein kinases are a group of enzymes that move a phosphate group onto proteins, in a process called phosphorylation. This functions as an on/off switch for many cellular processes, including metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. They also function in embryonic development, physiological responses, and in the nervous and immune system. Abnormal phosphorylation causes many human diseases, including cancer, and drugs that affect phosphorylation can treat those diseases. Protein kinases possess a catalytic subunit which transfers the gamma phosphate from nucleoside triphosphates (almost always ATP) to the side chain of an amino acid in a protein, resulting in a conformational and/or dynamic changes affecting protein function. These enzymes fall into two broad classes, characterised with respect to substrate specificity: serine/threonine specific and tyrosine specific.
==== Systemic sickness ==== Since the 1990s, reviews of studies for causal relations between silicone-gel prosthetic breasts and systemic disease reported no causal relation to the occurrences of either systemic or autoimmune diseases; nonetheless, many women reported suffering neurological and rheumatological illnesses caused by failures of their prosthetic breasts. The study Long-term Health Status of Danish Women with Silicone Breast Implants (2004), reported that in relation to women of the general population, women with prosthetic breasts did not have a greater rate of incidence and diagnosis of autoimmune disease; that their rate of incidence for musculoskeletal disease was lower than the rate of incidence among women who had undergone other types of cosmetic surgery.
=== India and Nepal === Sickle cell disease is common in some ethnic groups of central India, where the prevalence has ranged from 9.4 to 22.2% in endemic areas of Madhya Pradesh, Rajasthan, and Chhattisgarh. It is also endemic among Tharu people of Nepal and India; however, they have a sevenfold lower rate of malaria despite living in a malaria infested zone.
William Henry Vanderbilt* (1841), eldest son of Cornelius Vanderbilt; president of the New York Central Railroad, Lake Shore and Michigan Southern Railway, Canada Southern Railway, and Michigan Central Railroad Robert Morrison Olyphant (1842), heir to trading company Olyphant & Co. and president of the Delaware and Hudson Railway Charles Carow* (1844), businessman son of shipping magnate Isaac Carow, father of first lady Edith Carow Roosevelt Frederic W. Rhinelander (1847), 3rd president of the Metropolitan Museum of Art William Backhouse Astor Jr. (1849), son of William Backhouse Astor Sr. and husband of Caroline Webster Schermerhorn Astor, co-founder of The Four Hundred list of socialites and Florida Yacht Club Robert L. Cutting Jr. (1856), banker and clubman, son of Robert L. Cutting '30 George Lovett Kingsland (1856), merchant and railroad executive, son of New York City mayor Ambrose Kingsland Goold H. Redmond (1857), banker and sportsman Charles Henry Marshall (1858), businessman, former commissioner of Docks and Ferries of the City of New York, grandfather of publisher Marshall Field IV John Crosby Brown (1859), heir to investment bank Brown Bros. & Co., which later became Brown Brothers Harriman & Co., the oldest private bank in the U.S. Emory McClintock (1859), actuary; president of the American Mathematical Society and the Actuarial Society of America Robert Goelet (1860), real estate developer Rutherfurd Stuyvesant (1863), socialite, heir to the Stuyvesant family fortune J.
Sources: en.wikipedia.org
In the UK no formal qualification or certification is required prior to becoming a phlebotomist as training is usually provided on the job. The NHS offers training with formal certification upon completion.
== In popular culture == In the episode of House, "Skin Deep", opioid antagonist drugs were administered in order to completely remove the patient's heroin induced addiction/withdrawal symptoms (during an induced coma in order to relieve the extreme pain of their use), so that an accurate diagnosis of paraneoplastic syndrome caused by cancer was differentiated. In an episode of Royal Pains, a character dangerously tries to undergo a procedure (and go under anaesthesia) in his own home. In an episode of Hannibal, Dr.Lecter administers Naloxone to Jack Crawford's wife after she tries to commit suicide by overdosing on morphine.
CEEs are prodrugs of the active forms of the estrogens. Sodium estrone sulfate is a prodrug of estrone, which in turn is a prodrug of estradiol, while sodium equilin sulfate is a prodrug of equilin and then of 17β-dihydroequilin. As such, the major active estrogens with CEEs are estradiol and 17β-dihydroequilin, which have potent estrogenic activity and account for most of the effects of CEEs. The 17α-estrogens in CEEs such as 17α-estradiol and 17α-dihydroequilin have low estrogenicity and are thought to contribute minimally to its effects. There are many different steroids in natural CEE products like Premarin, as many as 230 compounds and including even androgens and progestogens, but only the estrogens are present in sufficient amounts to produce clinically-relevant effects. A dosage of 0.625 mg/day oral CEEs has been found to increase SHBG levels by 100%. For comparison, 1 mg/day oral estradiol increased SHBG levels by 45%, while 50 μg/day transdermal estradiol increased SHBG levels by 12%. Ethinylestradiol is more potent in its effects on liver protein synthesis than either CEEs or estradiol, with 10 μg/day oral ethinylestradiol having been found to be approximately equivalent to 1.25 mg/day CEEs.
Higher level encryptions exist, the highest of these being M32. M32 and lower level encrypted signals are the province of Special Circumstances (SC). Use of M32 is reserved for extremely secret and reserved information and communication within Special Circumstances. That said, M32 has an air of notoriety in the Culture, and in the thoughts of most may best be articulated as "the Unbreakable, Inviolable, Holy of Holies Special Circumstances M32" as described by prospective SC agent Ulver Seich. Ships and Minds also have a slightly distasteful view of SC procedure associated with M32, one Ship Mind going so far as to object to the standard SC attitude of "Full scale, stark raving M32 don't-talk-about-this-or-we'll-pull-your-plugs-out-baby paranoia" on the use of the encryption.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.